About Day One
Day One is a publicly listed company based in San Francisco (United States) founded in 2018 by Sam Blackman, and was acquired by Servier in March 2026. It operates as an investigational cancer drugs, including pan-RAF inhibitors, are developed. It operates on a Direct-to-Consumer (D2C) model. Day One has raised $190 million across 2 funding rounds from investors including T. Rowe Price, Franklin Templeton and Janus Henderson Investors. The company has 181 employees. Day One has completed 1 acquisition, including Mersana. Its website dayonebio.com draws about 16 thousand monthly visits. Day One offers products and services including OJEMDAâ„¢ (tovorafenib) and Tovorafenib DAY301. Its focus areas include Biotechnology and Oncology. Its legal entity is Day One Biopharmaceuticals, Inc.
Company details
Day One Biopharmaceuticals, Inc. is engaged in the development of targeted therapies for cancer treatment, catering to both children and adults. The company operates within the biotechnology sector, emphasizing innovative drug development for oncology. Solutions such as OJEMDA (tovorafenib) are provided to address urgent medical needs. A search development strategy is employed to identify and advance the right programs for patients. The focus is maintained on disrupting traditional drug development to deliver better medicines faster.
- Headquarters San Francisco, United States
- Employees 181
- Founders Sam Blackman
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website dayonebio.com
- Social LinkedIn X
- Acquired by Servier (Mar 2026)
- Legal Name Day One Biopharmaceuticals, Inc.
- Annual Revenue$131.16 M (USD)0as on Dec 31, 2024
- Net Profit-$95.5 M (USD)49.45as on Dec 31, 2024
- EBITDA-$215.24 M (USD)-4.65as on Dec 31, 2024
- Total Equity Funding$190M (USD)
in 2 rounds
- Latest Funding Round$130M (USD), Series B
Feb 2021
- InvestorsT. Rowe Price
& 11 more
- Employee Count181
- Investments & Acquisitions
- Acquired byServier
(Mar 2026)
Products & Services of Day One
Day One offers a comprehensive portfolio of products and services, including OJEMDA™ (tovorafenib) and Tovorafenib DAY301.
A targeted therapy developed for cancer treatment purposes.
A drug candidate explored for oncology treatment solutions.
Funding Insights of Day One
Day One has successfully raised a total of $190M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $130 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $190M
- Total Rounds 2
- Last Round Series B — $130M
- First Round $60M
(May 2020)
- Investors Count 11
All 2 funding rounds of Day One with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2021 | $130M | Series B | – | RA Capital Management | |
| May 2020 | $60M | Series A | – | Canaan, Atlas Venture | – |
12 investors in total: 12 institutional.
Investors in Day One
Day One has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include T. Rowe Price, Franklin Templeton and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biotech startups are funded by this venture capital firm. | – | boxercap.com | San Diego, United States | |
US private equity investments are managed by BVF Partners. | – | bvflp.com | San Francisco, United States | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Private investment firm focused on multiple sectors | – | vikingglobal.com | Greenwich, United States | |
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Canaan is recognized as an early-stage venture capital firm. | 1987 | canaan.com | San Francisco, United States | |
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Investment and holding company controlled by Len Blavatnik | – | accessindustries.com | New York, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Diversified investment management services are offered globally by the firm. | 1947 | franklintempleton.com | New York, United States |
Investor details for Day One
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Day One
91 people are tracked at Day One (69 in leadership, 6 in board & advisors, 16 in team); the tracked headcount is 181.
| Name | Role | Group |
|---|---|---|
Sam Blackman | Co-Founder | Leadership |
Xiaomei L. | Sr Director, Head Of Medical Writing | Leadership |
Wesley Miller | Director Of Finance - Fp&a Supporting R&d And Commercial | Leadership |
Lydia Tang | Senior Director, People Operations | Leadership |
Justin Slawson | Senior Director, Corporate Development, Search & Evaluation | Leadership |
Davy Chiodin | Chief Development Officer | Leadership |
Brandy Peacock | Associate Director, QA Documentation And Training | Leadership |
Cydrienne Chatto | Director, Regulatory Science | Leadership |
Samuel Blackman | Head of R&D | Leadership |
Christa Kerkorian | Vice President Of Patient Advocacy | Leadership |
Michael Cox | VP of Clinical Development | Leadership |
Jeremy Bender | Chief Executive Officer | Leadership |
Jing Wang | Head, Clinical Pharmacology | Leadership |
Romy Topper-Cox | National Director Field Medical, Medical Affairs | Leadership |
Charles N. York II | Chief Operating and Financial Officer | Leadership |
Signe Thyssen | Director, Procure To Pay | Leadership |
Luis Pinzon | Director Commercial Training | Leadership |
Lauren Merendino | Chief Commercial Officer | Leadership |
Jaa Roberson | Chief People Officer | Leadership |
Ethan Cheung | Sr Director, IT Infrastructure & Security | Leadership |
71 more people are available in the full profile.
Complete people profiles for Day One
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Day One
Day One is a publicly listed company on the NASDAQ with ticker symbol DAWN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 May 2021
- Listed onNASDAQ: DAWN
- Listed entityDay One Biopharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS23954D1090
- Share price$21.53 (+0.19% on the day) · 2026-04-24
- Market capitalisation$2.22B
- EPS (diluted, trailing year)$-1.04
- Volume (last session)2,988,826
- Analyst consensusNeutral
Financials of Day One
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $131.2M | -$95.5M | -$215.2M |
| 2023 | – | -$188.9M | -$205.7M |
| 2022 | – | -$142.2M | -$146.4M |
| 2021 | – | -$70.6M | -$72.5M |
Detailed financial statements for Day One
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Day One
Day One has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Mersana.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Antibody-drug conjugates for cancer treatment are developed by Mersana. | mersana.com | Cambridge, United States | 2001 | Nov 2025 | $285M |
Complete acquisition details for Day One
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Day One
6 dated milestones of Day One across 8 years, from founding to its latest funding, stage changes and deals.
Web traffic of Day One
The website of Day One (dayonebio.com) receives about 15.8K visits a month and ranks #1,875,018 among all websites worldwide, #2,562 in Biotechnology and Pharmaceuticals.
- Monthly visits15.8K
▲ 33.7% vs previous month
- Unique visitors5.9K
per month
- Global rank#1,875,018
among all websites
- Category rank#2,562
Health · Biotechnology and Pharmaceuticals
- Bounce rate33%
- Pages per visit2.0
- Average visit1 min 08 sec
- DevicesDesktop 41% · Mobile 59%
Websites whose visitors overlap most with Day One. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| takedaoncology.com | 100% | 14.3K | #1,943,946 | View details |
Top companies in Oncology
10 companies that operate in the same segment as Day One (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Day One
Complete news archive for Day One
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Day One
Day One was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Day One is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Day One is a funded company, having raised a total of $190M across 2 funding rounds to date. The company's 1st funding round was a Series A of $60M, raised on May 2020.
Day One has 181 employees.
Annual revenue of Day One is $131.16M as on Dec 31, 2024.
Day One Biopharmaceuticals, Inc. is engaged in the development of targeted therapies for cancer treatment, catering to both children and adults. The company operates within the biotechnology sector, emphasizing innovative drug development for oncology. Solutions such as OJEMDA (tovorafenib) are provided to address urgent medical needs. A search development strategy is employed to identify and advance the right programs for patients. The focus is maintained on disrupting traditional drug development to deliver better medicines faster.
Day One offers OJEMDAâ„¢ (tovorafenib) and Tovorafenib DAY301.
Yes, Day One is publicly traded on NASDAQ under the ticker symbol DAWN.
Day One has made 1 acquisition, including Mersana.
Day One has 12 investors. Key investors include T. Rowe Price, Franklin Templeton, Janus Henderson Investors, RA Capital, and Servier.
Day One operates through Day One Biopharmaceuticals, Inc..
Yes. Day One was acquired by Servier in March 2026.